Cellexus Biosystems plc appoints Appropriate Technical Resources Inc. as US Distributor

June 18th 2007: Cellexus Biosystems plc (PLUS Markets: CBIO), specialist in the design, manufacture and commercialisation of novel disposable technology for growing cells, has entered into a non-exclusive distribution agreement with Appropriate Technical Resources, Inc. (ATR).

Under the agreement, ATR, one of the country’s major providers of fermentation equipment and cell culture systems, will distribute Cellexus Biosystems’ products throughout the US. The agreement marks a significant boost to the sales reach of Cellexus Biosystems within the US, and will provide its growing customer base with further local support. It represents a substantial milestone for both companies and is one of several steps that Cellexus is taking to expand its market share in the US.

Commenting on the agreement, CEO at Cellexus Biosystems, Dr Kevin Auton said:

“We are very pleased to enter into this formal agreement with ATR. We have worked quietly behind the scenes with ATR for six months, establishing a close relationship and planning how best to serve the world’s largest community of bioresearchers.

“As a partner, ATR are a great fit for us. They know our customers and the challenges that face them. They have a collaborative approach that our customers welcome and they’re recognised for their ability to sell and support bioreactor instrumentation and consumables.

“ATR will be supported by our applications laboratory facility in the Mountain Top Campus at Lehigh University (Pennsylvania, US). This laboratory will develop new protocols for cell culture, test new products that Cellexus are launching throughout 2007 and serve as a demonstration and support centre for ATR’s customers.”

ATR’s Vice President, LuAnn Bisciano commented:

“ATR is very excited about having the opportunity to work alongside Cellexus and to have been selected to bring CellMakerTM products to customers in the US. The Cellexus technology is the type of innovation that we know our customers have been seeking and we look forward to presenting these products to our customer base.

“We have sold over 5,000 flask shaker systems into the US market, and many of our customers are looking to scale-up to higher volumes but are discouraged by the thought of using a traditional bioreactor. The CellMaker Lite2TM will give our customers the opportunity to scale-up without the complexity of using a glass or stainless steel bioreactor. The CellMaker product range is a much needed option in the market.”

Ends

Further information:

Cellexus Biosystems plc:
Dr Kevin Auton
12 Ramsay Court
Hinchingbrooke Business Park
Huntingdon
Cambridgeshire PE29 6FY
United Kingdom
+44 1480 453 858
kevin.auton@cellexusbiosystems.com
www.cellexusbiosystems.com

Appropriate Technical Resources (ATR):
LuAnn Biscano
PO Box 460
Laurel,
MD 20725-0460
USA
+1 800 827 5931
lkb@atrbiotech.com
www.atrbiotech.com

Hybridan LLP, Cellexus Biosystems’ broker:
Claire Noyce
Stephen Austin
+44 20 3159 5085

JM Finn & Co, corporate adviser:
Clive Carver
+44 207 600 1659

Media enquiries:
Capital MS&L, PR advisers for Cellexus Biosystems
Mary Clark/ Peter Curtain
+44 20 7307 5330
peter.curtain@capitalmsl.com 
www.captialmsl.com

Trade Press enquiries:
Not This Limited, Marketing advisors for Cellexus Biosystems
Jessica Auton
+44 1480 352 821
jessica.auton@notthislimited.co.uk


Notes to editors:
Cellexus Biosystems has developed a range of value-added disposables to help researchers in the biopharmaceutical industry and academia, develop new biopharmaceutical products from cell lines. Biopharmaceuticals are the new breed of medicines, generated by culturing cells in bioreactors. These medicines are often proteins, such as antibodies or can be vaccines. The potential of future medical treatments offered by stem cell research would also fall within this category. Sales of biopharmaceuticals reached US$60 billion in 2005 and are growing at 20% per annum.

The Company has already developed a family of products. Three products have been developed all based around the core technology - the CellexusBagTM – and are marketed under the name: CellMaker Lite2TM. These products potentially offer significant technological improvements for cell culture and cell growth in the developing disposables market.

Unlike competitive products, the CellexusBag products do not need to be stirred, shaken, rocked or rolled, which means the equipment used to manage the cell culture process is very simple and inexpensive. A patent application protecting the Company’s intellectual property was filed in December 2005.

Images of the CellMaker Lite2 can be downloaded from the Company’s website
http://www.cellexusbiosystems.com/index_files/CellexusBiosystemsMediaResources.htm

Appropriate Technical Resources (ATR) was founded in 1980 and is a private owned company, specialising in the sale, support and manufacture of a range of products for cell culture and fermentation. ATR’s policy is to provide superior products at very competitive prices. For more than 15 years, ATR have provided products and services to government, educational and private institutions and are dedicated to customer service. www.atrbiotech.com